Youssef Afifi: The Thrombocytosis–Bleeding Paradox
Youssef Afifi, Consultant of Hematology and Internal Medicine at Cleopatra Hospitals Group, Consultant of Hematology and BMT at Police Academy, shared a post on LinkedIn:
“The thrombocytosis/bleeding paradox
More platelets mean more blood clots, right?
Actually, no. In hematology, we have a fascinating phenomenon where having ‘too many’ platelets dramatically increases the risk of bleeding.
This phenomenon perfectly illustrates why hematology is not always straight forward.
In myeloproliferative neoplasms like Essential Thrombocythemia (ET), a moderate increase in platelets predictably raises the risk of thrombosis. But once that platelet count crosses an extreme threshold – typically more than 1,000,000 or 1,500,000/μL—the script flips.
The patient’s bleeding risk skyrockets.
Why does this happen?
It comes down to ‘Acquired von Willebrand Syndrome (aVWS)‘
Normally, von Willebrand Factor (vWF) acts like the biological glue that helps platelets stick to damaged blood vessels and to each other. The largest vWF molecules (high-molecular-weight multimers) are the stickiest and most effective.
When a patient has a massive overproduction of platelets, these millions of circulating platelets rapidly bind to and clear out those crucial vWF multimers.
Essentially, the sheer volume of platelets exhausts the body’s supply of its best clotting glue.
The result? A lot of functionally useless because they can’t stick together.
This is why managing extreme thrombocytosis requires nuance.
Automatically giving aspirin to a patient with a platelet count of 1.5 million to “prevent clots” can actually trigger severe gastrointestinal or mucosal bleeding.
Instead, the focus often shifts to cytoreductive therapy to bring the absolute count down, which allows the vWF levels to recover and normalizes hemostasis.”
Stay updated with Hemostasis Today.
-
Nov 8, 2026, 11:56Why Genetic Predisposition Does Not Always Lead to Thrombosis – Stork Genetics
-
Nov 8, 2026, 11:45Sher-Lu Pai: Investigating Intracardiac Thrombosis and Its Management in Liver Transplantation
-
Nov 8, 2026, 11:25Mehmet Cilingiroglu: Navigating Anticoagulation Choices in Acute Coronary Syndrome PCI
-
Nov 8, 2026, 07:16Gilberto de lima Lopes Junior: The Cardiovascular Consequences of Cancer in Younger Patients
-
Nov 8, 2026, 06:51Haney Mallemat: Key Principles and Pitfalls of LVAD Emergencies
-
Nov 8, 2026, 06:31Maria Omer: Clinical Recognition and Management of Cavernous Sinus Thrombosis
-
Nov 8, 2026, 06:16Natasha Jolakoski: University of New Mexico Hospital Promotes PGY-2 Thrombosis and Hemostasis Management Pharmacy Residency
-
Nov 8, 2026, 05:47Safaa Hilal: POCUS in the Evaluation of Perioperative Troponin Elevation
-
Nov 8, 2026, 05:34Eugene Bolotin: Thrombosis and Survival in Pancreatic Cancer